EN DE
Watch ImmuneOncia for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ImmuneOncia (424870) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of ImmuneOncia stock KRW 1,230, price KRW 2,485, that is 50.5% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

I ImmuneOncia logo Thin data Nov 10, 2026

ImmuneOncia

424870 · KQ
Very expensive, weak quality

Our calculation puts a fair price 51% below what the stock costs today.

Fair value 1,230 KRW · Strongly overvalued
Quality 39/100
Weak Growth (revenue 3y −75.7 %/yr in KRW)
Negative free cash flow
Trails peers (1/5)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch ImmuneOncia for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14,286 KRW 2,380 KRW Fair Value 1,230 KRW May 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

18‑month range 2,380 KRW – 14,286 KRW · fair‑value band 922.17 KRW – 1,537 KRW · the 2,485 KRW price screens above the 1,230 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow ImmuneOncia in your weekly email

Every Wednesday you see whether ImmuneOncia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer.

Show moreShow less

It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer.

The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy. The company was incorporated in 2016 and is headquartered in Yongin-si, South Korea.

ImmuneOncia Therapeutics, Inc. operates as a subsidiary of Yuhan Corporation.

Stock analysis

ImmuneOncia (424870) currently trades at 2,485 KRW, while our estimate is 1,230 KRW, 51% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 922.17 KRW (bear) to 1,537 KRW (bull), the price of 2,485 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ImmuneOncia reported revenue of 111M KRW in FY2025 versus 35.9M KRW in FY2021, a compound +32.6%/yr. Reported net income was −27.4B KRW in FY2025.

Key figures

Market cap 230B KRW (≈ $172M) Micro · EPS (TTM) −321.08 KRW · Return on equity −39.7% · Return on assets (EBIT) −46.6% (5-year average) · Free cash flow −23.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −51%, 424870 screens richer than that median.

Fair Value

Bear 922.17 KRW Fair Value 1,230 KRW Bull 1,537 KRW
Price 2,485 KRW · Downside -50.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−83.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−75.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33,094.1% (2021) → −25,185.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

424870 screens overvalued: fair value 51% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ImmuneOncia with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −50.5% · Bottom 25%
Profitability
Return on assets −82.6% · Bottom 25%
Operating margin (12 months) 0.0% · Above median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 424870
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 424870
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 424870
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 424870
argenx SE ARGX $971.55 $908.40 −7% vs 424870
CSL Limited CSL A$201.68 A$181.40 −10% vs 424870
Moderna, Inc MRNA $250.83 $158.70 −37% vs 424870
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 424870
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 424870
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 424870

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ImmuneOncia: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ImmuneOncia Fair Value". https://www.fairvalue-calculator.com/stock/424870

Frequently asked questions

Is ImmuneOncia (424870) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,230 KRW versus a price of 2,485 KRW, about 51% lower (overvalued).
What is the fair value of 424870?
Our estimate for ImmuneOncia is 1,230 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 2,485 KRW.
What is the quality score of 424870?
ImmuneOncia has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ImmuneOncia (424870)?
Our calculated price target is the estimate of 1,230 KRW (as of Nov 10, 2026). Cautious scenario 922.17 KRW, optimistic scenario 1,537 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the ImmuneOncia stock forecast for 2026?
Our estimate puts fair value at 1,230 KRW, about 51% lower versus a price of 2,485 KRW (overvalued). Cautious scenario 922.17 KRW, optimistic scenario 1,537 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of ImmuneOncia (424870)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ImmuneOncia it is 1,230 KRW per share (as of Nov 10, 2026), against a price of 2,485 KRW.
Is ImmuneOncia stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 424870 trades above its calculated fair value: price 2,485 KRW, fair value 1,230 KRW, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 424870?
No. The price is what the market pays today (2,485 KRW); the fair value is what the company's own numbers justify (1,230 KRW). For ImmuneOncia the two are 1,255 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ImmuneOncia worth?
The market values ImmuneOncia at about 230B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 2,485 KRW; our models calculate a fair value of 1,230 KRW per share.
What do the bullish and bearish scenarios say about 424870?
Our models span a range for ImmuneOncia: cautious scenario 922.17 KRW, base 1,230 KRW, optimistic 1,537 KRW per share (as of Nov 10, 2026, price 2,485 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ImmuneOncia (424870)?
Balance-sheet figures for ImmuneOncia (as of Nov 10, 2026): return on equity −39.7%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 424870 from its 52-week high?
ImmuneOncia trades at 2,485 KRW, about 83% below its 52-week high of 14,286 KRW and 4% above the low of 2,380 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,230 KRW is for.
Which stocks are comparable to ImmuneOncia?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ImmuneOncia stock attractive at the current price?
The data as of Nov 10, 2026: price 2,485 KRW, calculated fair value 1,230 KRW (−51%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. ImmuneOncia itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ImmuneOncia (424870)?
The closing price on Nov 10, 2026 was 2,485 KRW. Our estimate is 1,230 KRW, about 51% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ImmuneOncia right now?
The price sits above even our optimistic bull case (1,537 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of ImmuneOncia

How large is the market capitalisation of ImmuneOncia (424870)?
The market capitalisation of ImmuneOncia is 230B KRW (≈ $172M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ImmuneOncia (424870)?
Earnings per share at ImmuneOncia are −321.08 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ImmuneOncia (424870)?
The return on equity (ROE) of ImmuneOncia is −39.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ImmuneOncia (424870)?
On an EBIT basis the return on assets of ImmuneOncia is −46.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does ImmuneOncia (424870) generate?
The free cash flow of ImmuneOncia is −23.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ImmuneOncia in the live analysis

One click puts ImmuneOncia on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.